Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more

Recent & Breaking News (NDAQ:ALDX)

Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes

PR Newswire June 25, 2018

Aldeyra Therapeutics Announces 2018 Research Day

PR Newswire June 20, 2018

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

PR Newswire May 15, 2018

Aldeyra Therapeutics, Inc. to Host Earnings Call

Accesswire May 15, 2018

Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy

PR Newswire May 10, 2018

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results

PR Newswire May 9, 2018

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting

PR Newswire May 1, 2018

Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial

PR Newswire April 24, 2018

Aldeyra Therapeutics Announces Year End 2017 Financial Results

PR Newswire March 29, 2018

Aldeyra Therapeutics, Inc. to Host Earnings Call

Accesswire March 29, 2018

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results

PR Newswire March 22, 2018

Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases

PR Newswire February 27, 2018

Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

PR Newswire February 21, 2018

New Research Coverage Highlights Carter's, Invacare, Hortonworks, BGC Partners, Hyatt Hotels, and Aldeyra Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire February 9, 2018

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial

PR Newswire January 30, 2018

Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

PR Newswire November 29, 2017

Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

PR Newswire November 9, 2017

Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

PR Newswire November 7, 2017

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

PR Newswire November 2, 2017

Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

PR Newswire October 25, 2017